collected the anti-SARS-CoV-2 antibody data of patients with COVID-19 longitudinally at three time points (median 2.1, 5.6, and 8.4 months), and found that antibodies targeting four antigens (the trimeric Spike, Spike-RBD, Nucleocapsid, and the Nucleocapsid RNA Binding Domain) decreased within 8 months after infection, and showed a two-phase decay with a more obvious decrease during the first 6 months PSO. This evidence concerns the gene CHMP5 and COVID-19.